NEW YORK, NY / ACCESSWIRE / February 11, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Desktop Metal, Inc. (NYSE:DM)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/desktop-metal-inc-loss-submission-form?prid=23632&wire=1
Lead Plaintiff Deadline: February 22, 2022
Class Period: February 17, 2021 – November 15, 2021
Allegations against DM include that: (1) there were deficiencies in Desktop Metals’ acquisition EnvisionTEC’s manufacturing and product compliance practices and procedures; (2) the foregoing deficiencies presented a material risk to the commercialization of EnvisionTEC’s products; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Tal Education Group (NYSE:TAL)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tal-education-group-loss-submission-form?prid=23632&wire=1
Lead Plaintiff Deadline: April 5, 2022
Class Period: April 26, 2018 – July 22, 2021
Allegations against TAL include that: (a) TAL’s revenue and operational growth was the result of deceptive marketing tactics and illicit business practices that flouted Chinese laws, regulations and policies, and exposed the Company to an extreme risk that more draconian measures would be imposed on the Company; (b) TAL had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of the Company’s programs to its customers, the creation of fake customer reviews designed to fraudulently lure new customers to TAL programs, the misrepresentation of teacher qualifications and course qualities, and the marketing of rigged promotional events; (c) TAL had defied Chinese policies designed to alleviate the burden imposed by tutoring services on students and their families, including by imposing hefty advances and recurring debt payments on course enrollees, by offering courses designed to give affluent students unfair advantages, by holding courses outside of allowable tutoring hours, and by linking for-profit courses to government-mandated schooling; (d) as a result of the foregoing, TAL was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the Company’s business and financial interests; and (e) as a result of the foregoing, TAL’s historical growth was not sustainable or the result of legitimate business tactics as represented, and defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and lacked a reasonable factual basis.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?prid=23632&wire=1
Lead Plaintiff Deadline: April 11, 2022
Class Period: May 28, 2021 – November 26, 2021
Allegations against FENC include that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE : The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/688468/SHAREHOLDER-ALERT-DM-TAL-FENC-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines